WASHINGTON & CARLSBAD, Calif. & BOSTON--()--The fifth annual international partnering conference, BioPharm America™ 2012, wrapped up last week in Boston. There were over 750 delegates representing 462 companies from 30 countries engaged in 1,846 one-to-one partnering meetings with 652 licensing opportunities, confirming BioPharm America as the premier destination for forming partnerships between emerging innovator and start-up companies, and large multinational firms.
“BioPharm America was once again a success for the local Massachusetts life sciences community and our colleagues from around the world”
“BioPharm America continues to bring the most talented, innovative leaders of biotech and pharma to Boston every year,” said Carola Schropp, President of EBD Group. “The goal of partnering, the goal of this event, is the improvement of healthcare for all, and ultimately providing patients the treatments and therapies they need. This can only be achieved by coupling novel research with the right investor partners. That is what BioPharm America delivers year after year.”
The dynamic program began with an announcement of the 2012 Fierce 15 by FierceBiotech Editor-in-Chief John Carroll, and a keynote address from David Meeker, President and CEO of Genzyme, a Sanofi company. Roundtable discussions on diagnostics, open access and diabetes, and spotlight and business development panels with topics ranging from major deals of 2012 to operationalizing external R&D featured high level executives and CEOs from leading pharmaceutical and biotech companies. Delegates were also some of the first to hear about the formation of TransCelerate BioPharma, a new non-profit organization focused on accelerating the development of new medicines that was announced by Carola Schropp on behalf of newly appointed interim CEO of TransCelerate, Garry Neil.
The event, organized by EBD Group, the leading partnering firm for the life science industry, was held September 19–21, 2012 at the Westin Boston Waterfront in Boston, MA in collaboration with the Massachusetts Biotechnology Council (MassBio).
“BioPharm America was once again a success for the local Massachusetts life sciences community and our colleagues from around the world,” said Robert K. Coughlin, President and CEO of MassBio. “The discussion from industry leaders narrowed in on deconstructing the critical challenges the industry faces today and fleshing out potential opportunities for continued growth. The focus on partnering allowed stakeholders to make the connections they need to continue to grow, thrive, and solve unmet medical needs.”
An impressive mix of companies, partners and local large pharmaceuticals attended BioPharm America 2012 including Alexion Pharmaceuticals, Amgen, AstraZeneca, Bayer HealthCare, Bristol-Myers Squibb, GlaxoSmithKline, Ironwood Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire, and Takeda.
View video highlights from BioPharm America 2012 online at http://www.ebdgroup.com/bpa/media/videos.php.
About BioPharm America 2012
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Additional links and information:
Follow BioPharm America 2012 on Twitter: twitter.com/ebdgroup (hashtag: #BPA12)
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and healthcare, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- Partnering for Global Impact®, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
EBD Group’s sophisticated web-based partnering service, partneringONE®, is also used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences all year long.
Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.